Comparison of Three Ki-67 Index Quantification Methods and Clinical Significance in Pancreatic Neuroendocrine Tumors
- 447 Downloads
The Ki-67 index is essential in the pathological reports for pancreatic neuroendocrine tumors. There are three methods to determine the Ki-67 index including eyeball estimation, manual counting, or automated digital imaging analysis. The goal of this study was to compare the three quantification methods with the clinical outcome to determine the best method for clinical practice. Ki-67 immunostaining was performed on 97 resected pancreatic neuroendocrine tumors. The three methods of quantification were employed: (1) an average of eyeball estimation by three pathologists; (2) manual counting of at least 500 tumor cells; and (3) digital imaging analysis quantitation by selecting 8–10 hot spot regions. All tumors were graded according to the 2010 WHO grading system. The three quantification methods for the Ki-67 index had almost perfect agreement. The concordance between manual counting and digital imaging analysis and between manual counting and average eyeball estimation were 0.97 and 0.88, respectively. The concordance among the three pathologists’ eyeball estimation was 0.86. All three methods correlated with patients’ survival using the 2010 WHO grading system. Eyeball estimation scores were significantly less than those of the other two methods and tended to downgrade more tumors to grade 1, but they had higher predictive ability for survival and recurrence. The WHO system using the mitotic rate could also separate patients with different survival and even downgraded more tumors to grade 1. The results suggest the necessity of a consensus among pathologists for the method to determine the Ki-67 index and proper cutoff of the Ki-67 index for better clinical correlation.
KeywordsPancreatic neuroendocrine tumor Ki-67 Mitosis Digital imaging analysis Prognosis
Conflict of Interest
The authors have no conflicts of interest or funding to disclose.
- 8.DeLellis RA LR, Heitz PU, and Eng C. Pathology & Genetics, Tumors of Endocrine Organs 2004.Google Scholar
- 10.Yamaguchi T, Fujimori T, Tomita S, Ichikawa K, Mitomi H, Ohno K, et al. Clinical validation of the gastrointestinal NET grading system: Ki67 index criteria of the WHO 2010 classification is appropriate to predict metastasis or recurrence. Diagn Pathol. 2013;8:65.PubMedCentralPubMedCrossRefGoogle Scholar
- 11.Bosman F, Carneiro F, Hruban R, Theise N. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer; 2010.Google Scholar
- 13.Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, O'Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen CY, Washington MK, Wiedenmann B, Yao J. Pathology Reporting of Neuroendocrine Tumors: Application of the Delphic Consensus Process to the Development of a Minimum Pathology Data Set. Am J Surg Pathol 2010;34(3):300–13PubMedCrossRefGoogle Scholar
- 19.McCall CM, Shi C, Cornish TC, Klimstra DS, Tang LH, Basturk O, et al. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. The American journal of surgical pathology. 2013;37(11):1671–7.PubMedCentralPubMedCrossRefGoogle Scholar
- 22.Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. The American journal of surgical pathology. 2012;36(12):1761–70.PubMedCrossRefGoogle Scholar
- 34.Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008;14(23):7798–803.CrossRefGoogle Scholar
- 37.Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez JA, Martinez Del Prado MP, Alonso Orduna V, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010;21(9):1794–803.PubMedCrossRefGoogle Scholar